Kathleen Scott - 12 Feb 2024 Form 4 Insider Report for NKGen Biotech, Inc. (NKGN)

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	NKGN	Stock Option (right to buy)	Award	$0	+300,000		$0.000000	300,000	12 Feb 2024	Common Stock	300,000	$1.62	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Id	Content
F1	On February 12, 2024, the reporting person was granted 300,000 options pursuant to the Company's 2023 Equity Incentive Plan, vesting in equal installments on the first of each month, beginning October 1, 2023, and ending October 1, 2026, subject to the Reporting Person's continued service with the Issuer on each respective vesting date.